Sanofi has made a strategic investment of $27 million in Ventyx Biosciences, a company developing therapies for neuroinflammatory and neurodegenerative conditions. The investment will support the development of VTX3232, a promising drug candidate for Parkinson’s disease and obesity, with data expected in 2025.